EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GDF‐15 is associated with sarcopenia and frailty in acutely admitted older medical patients

Rikke S Kamper iD, Hanne Nygaard, Louis Praeger-Jahnsen, Anette Ekmann, Sisse Bolm Ditlev, Martin Schultz, Sofie Krarup Hansen, Pernille Hansen, Eckart Pressel, Charlotte Suetta

Journal of Cachexia, Sarcopenia and Muscle · 2024-08 · 15 (4) · 1549-1557

DOI: 10.1002/jcsm.13513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 18.06.2024. Verfasst von Rikke S Kamper und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric & Palliative Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Biomarkers, Frailty, Growth Differentiation Factor 15, Sarcopenia. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Growth differentiation factor‐15 (GDF‐15) has been associated with senescence, lower muscle strength, and physical performance in healthy older people. Still, it is not clear whether GDF‐15 can be utilized as a biomarker of sarcopenia and frailty in the early stages of hospitalization. We investigated the association of plasma GDF‐15 with sarcopenia and frailty in older, acutely admitted medical patients.

Methods

The present study is based on secondary analyses of cross‐sectional data from the Copenhagen PROTECT study, a prospective cohort study including 1071 patients ≥65 years of age admitted to the acute medical ward at Copenhagen University Hospital, Bispebjerg, Denmark. Muscle strength was assessed using handgrip strength, and lean mass was assessed using direct segmental multifrequency bioelectrical impedance analyses and used to clarify the potential presence of sarcopenia defined according to guidelines from the European Working Group on Sarcopenia in Older People. Frailty was evaluated using the Clinical Frailty Scale. Plasma GDF‐15 was measured using electrochemiluminescence assays from Meso Scale Discovery (MSD, Rockville, MD, USA).

Results

We included 1036 patients with completed blood samples (mean age 78.9 ± 7.8 years, 53% female). The median concentration of GDF‐15 was 2669.3 pg/mL. Systemic GDF‐15 was significantly higher in patients with either sarcopenia ( P < 0.01) or frailty ( P < 0.001) compared with patients without the conditions. Optimum cut‐off points of GDF‐15 relating to sarcopenia and frailty were 1541 and 2166 pg/mL, respectively.

Conclusions

Systemic GDF‐15 was higher in acutely admitted older medical patients with sarcopenia and frailty compared with patients without. The present study defined the optimum cut‐off for GDF‐15, related to the presence of sarcopenia and frailty, respectively. When elevated above the derived cutoffs, GDF‐15 was strongly associated with frailty and sarcopenia in both crude and fully adjusted models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersFrailtyGrowth Differentiation Factor 15SarcopeniaAgedAged, 80 and overFemaleHumansMaleCross-Sectional StudiesHospitalizationProspective Studies

Stichwörter der Autor:innen

BiomarkerFrailtyGDF‐15Old ageSarcopeniaSenescence

Substanzen

BiomarkersGDF15 protein, humanGrowth Differentiation Factor 15

Autor:innen und Institutionen

  • Department of Geriatric & Palliative Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • CopenAge, Copenhagen Center for Clinical Age Research, University of Copenhagen, Copenhagen, Denmark.
  • Department of Emergency Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Geriatrics, Copenhagen University Hospital, Hvidovre and Amager, Hvidovre, Denmark.
  • Department of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Rikke S Kamper

Förderung

  • Novo Nordisk Foundation
  • Novo Nordisk Fonden

Zitieren

APA

Kamper, R. S., Nygaard, H., Praeger-Jahnsen, L., Ekmann, A., Ditlev, S. B., Schultz, M., Hansen, S. K., Hansen, P., Pressel, E., & Suetta, C. (2024). GDF‐15 is associated with sarcopenia and frailty in acutely admitted older medical patients. Journal of Cachexia, Sarcopenia and Muscle, 15(4), 1549-1557. https://doi.org/10.1002/jcsm.13513

Vancouver

Kamper RS, Nygaard H, Praeger-Jahnsen L, Ekmann A, Ditlev SB, Schultz M, et al. GDF‐15 is associated with sarcopenia and frailty in acutely admitted older medical patients. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(4):1549-1557. doi:10.1002/jcsm.13513

BibTeX
@article{Kamper2024,
  author = {Kamper, Rikke S and Nygaard, Hanne and Praeger-Jahnsen, Louis and Ekmann, Anette and Ditlev, Sisse Bolm and Schultz, Martin and Hansen, Sofie Krarup and Hansen, Pernille and Pressel, Eckart and Suetta, Charlotte},
  title = {GDF‐15 is associated with sarcopenia and frailty in acutely admitted older medical patients},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  volume = {15},
  number = {4},
  pages = {1549--1557},
  doi = {10.1002/jcsm.13513}
}
Kostenlos starten →